Multiple Myeloma

Learn about the newest therapies, interventions, and clinical research on multiple myeloma (MM). Cancer Nursing Today provides the latest clinical data and insights on screening for early detection, COVID-19 vaccine responses in patients with MM, and more. From treatment developments for relapsed/refractory MM and imaging techniques to the latest in CAR T-cell therapy, explore the latest outcomes in MM.

iStopMM Study: Population-Based Prevalence of Smoldering Multiple Myeloma

iStopMM Study: Population-Based Prevalence of Smoldering Multiple Myeloma

Ariel Jones

Conferences | December 17, 2021

Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study identified epidemiological and clinical characteristics of smoldering multiple myeloma (SMM) in a general population for the first time. Based on data from iStopMM’s 75,000 participant cohort, the study’s lead author, Sigrun Thorsteindotter, MD, PhD, and his team reported that the prevalence of SMM in persons aged 40 years or older is 0.53%. ...

Advertisement

Latest News

iStopMM Study: Population-Based Prevalence of Smoldering Multiple Myeloma

iStopMM Study: Population-Based Prevalence of Smoldering Multiple Myeloma

Ariel Jones

Conferences | December 17, 2021

This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.

$Daratumumab-Based Triplet Regimen in Real-World Patients With Relapsed or Refractory Multiple Myeloma$

Daratumumab-Based Triplet Regimen in Real-World Patients With Relapsed or Refractory Multiple Myeloma

Ariel Jones

Conferences | December 17, 2021

Researchers evaluated real-world data on DVd for treatment of patients with relapsed or refractory multiple myeloma.

Multiple Myeloma and Waldenström Macroglobulinemia Patients Have Impaired COVID-19 Vaccine Responsiveness

Multiple Myeloma and Waldenström Macroglobulinemia Patients Have Impaired COVID-19 Vaccine Responsiveness

Conferences | December 11, 2021

Both are malignancies associated with significant immunoparesis.

$Utility of IMWG Frailty Scoring in Patients With Relapsed/Refractory Multiple Myeloma$

Utility of IMWG Frailty Scoring in Patients With Relapsed/Refractory Multiple Myeloma

Ariel Jones

Conferences | December 11, 2021

Fabio Efficace, PhD, and a team of researchers investigated IMWG frailty scoring in patients with previously treated disease.

Results from the iStopMM Study Suggest MGUS Screening Enables Early Detection and Intervention

Results from the iStopMM Study Suggest MGUS Screening Enables Early Detection and Intervention

Ariel Jones

Conferences | December 11, 2021

Researchers explored whether screening for MGUS could increase the frequency of patients with MM being diagnosed.

Isatuximab Plus RVd Produces Better MRD Negativity Rates Than RVd Alone

Isatuximab Plus RVd Produces Better MRD Negativity Rates Than RVd Alone

Ariel Jones

Conferences | December 11, 2021

This is according to findings from a phase III study presented during the 2021 ASH Annual Meeting.

Advertisement

Knowledge Hubs

GI Cancer

GI Cancer

GVHD

GVHD

Hematology & Blood Cancer

Hematology & Blood Cancer

Multiple Myeloma

Multiple Myeloma

Conference Highlights

Caregivers, Patients Have Different Decision-Making Support Needs

June 16, 2022

Nurse Monitoring Could Prevent Symptoms Related to Targeted, Immune Therapies

June 16, 2022

Automated Coaching with NP Follow-up Effectively Reduced Symptom Burden

June 16, 2022

Did Updated FDA Guidance Increase Inclusion of Patients With Brain Metastases in Breast Cancer Trials?

June 14, 2022

Palliative Care Consults Can Be Improved in Patients With Metastatic Breast Cancer

June 14, 2022

Study Identifies Ways to Increase Representation of Black Patients in Breast Cancer Clinical Trials

June 14, 2022

Caregivers, Patients Have Different Decision-Making Support Needs

June 16, 2022

Nurse Monitoring Could Prevent Symptoms Related to Targeted, Immune Therapies

June 16, 2022

Advertisement

Advertisement

Popular Stories

Researchers Discover Signature to Predict Response to Pembrolizumab

Keightley Amen

Conferences | June 2, 2022

The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.

Study Examines COVID-19 Vaccine Efficacy in Patients With Breast Cancer

Keightley Amen

Conferences | June 2, 2022

Many studies are examining COVID-19's impact on particular subgroups of patients with cancer.

Recognizing Compassion Fatigue

Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®

Best Practices | April 22, 2022

Oncology nurses experience stress from many different directions—time pressures, nursing shortages, complex cancer ...

670 Madison Ave.

Manalapan, NJ 07726

Connect

Our Network

Blood Cancers Today

GU Oncology Now

Urban Health Today

About Us

Editorial Policy

© 2022 Mashup Media, LLC. All rights reserved.

Terms of Use | Privacy Policy